D. E. Shaw & Co., Inc. Aurinia Pharmaceuticals Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 81,742 shares of AUPH stock, worth $447,128. This represents 0.0% of its overall portfolio holdings.
Number of Shares
81,742
Previous 92,562
11.69%
Holding current value
$447,128
Previous $832,000
50.84%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding AUPH
# of Institutions
205Shares Held
55.6MCall Options Held
838KPut Options Held
1.18M-
Armistice Capital, LLC New York, NY12.3MShares$67.1 Million0.84% of portfolio
-
Black Rock Inc. New York, NY8.66MShares$47.4 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$21.7 Million1.4% of portfolio
-
State Street Corp Boston, MA2.77MShares$15.2 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.15MShares$11.8 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $776M
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...